Methuen, Massachusetts-based Alcanza Clinical Research announced on April 9 its acquisition of Innovation Medical Research Center, a multi-specialty clinical research center in Palmetto Bay, Florida.
Innovation conducts Phase I to Phase IV clinical trials in key therapeutic areas such as cardiology, dermatology, endocrinology, gastroenterology, infectious disease, internal medicine, nephrology, neurology, psychiatry, rheumatology and women’s health.
Alcanza Clinical Research is a network of research facilities focused on bringing clinical trial opportunities involving life-changing treatments and vaccines to all patients, especially those from underrepresented communities. With locations in Alabama, Florida, Georgia, Massachusetts, Michigan, New Hampshire, South Carolina and Virginia, it specializes in a range of conditions across psychiatry, neurology, dermatology and infectious disease therapeutic areas.
This transaction marks Alcanza’s ninth acquisition since 2021 and enables the company to expand its therapeutic area capabilities and diversity of study participants. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 11th clinical trials transaction of 2024. There were 42 clinical trials deals announced during 2023, a 40% increase from the 30 deals announced during 2022.
